On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health had granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a heterologous booster for those previously vaccinated with mRNA vaccines. The permit was based on the Israeli Advisory Committee on Epidemics’ recommendation.

Nuvaxovid has received authorization for use in adults aged 18 and older from more than 40 markets, including the U.S. and from the World Health Organization. In the 12 through 17 year-old population, the vaccine has been authorized in more than 10 markets including the U.S., the European Union, and the United Kingdom. Nuvaxovid has also been authorized in the European Union, Japan, Australia, New Zealand, and Switzerland as a booster in adults aged 18 and older. The vaccine is actively under review in other markets.